Functional studies are now warranted to illustrate the exact biological function of SETD2 in AML, but our data add to a growing body of evidence suggesting a role for SETD2 and H3K36me3 in AML that may be developed for the exploitation of novel therapeutic target. Here, SETD2 is linked to acute myeloid leukemia.